Impact of dopamine replacement therapy on shame in Parkinson’s disease patients
Objective: This study aims to investigate the effect of dopaminergic replacement therapy (DRT) on shame using emotional dynamic rating scales during ON and OFF-DRT states.…Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson’s disease.The AMBITIOUS Study Protocol
Objective: To determine in Parkinson’s disease (PD) patients carrying GBA mutation the role of Ambroxol (ABX) on the progression of cognitive performance (primary aim), motor…Feasibility and acceptability of implementing dignity therapy as a supportive intervention for people with movement disorders.
Objective: To determine the feasibility and acceptability of implementing Dignity Therapy (DT) in a neuropalliative clinic, and to determine preliminary efficacy. Background: Awareness of the…Clinical and radiological characteristics of elder patients of Parkinson’s disease with the onset age of more than 80 years old
Objective: We investigated clinical and radiological findings of elder PD patients with the onset of more than 80 years old using clinical examinations, brain CT/MRI…Clinical implication of small vessel disease burden on deep brain stimulation outcome in Parkinson’s disease
Objective: We aimed to investigate the correlation between the small vessel disease (SVD) burden and the 1-year outcome after the globus pallidus interna (GPi) deep…Normative values for the Instrumented Timed Up and Go test in Parkinsonian populations
Objective: This study aims to define normative values for the Instrumented Timed Up and Go test using wearable inertial sensors in people affected by Parkinson’s…Diagnosis of Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy with 7T-MRI substantia nigra imaging
Objective: To detect the signal change of nigrosome-1 in 7T-MRI and its diagnostic and differential diagnostic efficacy as the imaging biomarker of PD, MSA-P, MSA-C…Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.
Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…Asymmetric synaptic density and glucose consumption in subjects with non-demented Parkinson’s Disease, as measured with [11C]UCB-J and [18F]FDG PET.
Objective: The objective of this study was to investigate asymmetric synaptic density and glucose consumption in moderate-stage non demented PD patients and the association between…Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials
Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…
- « Previous Page
- 1
- …
- 193
- 194
- 195
- 196
- 197
- …
- 436
- Next Page »